Baseline characteristics | Usual care (n=122) | CRT-CPW (n=115) | P value* |
Male | 90 (73.8%) | 81 (70.4%) | 0.66 |
Age (years) | 0.16 | ||
18–64 | 35 (28.7%) | 24 (20.9%) | |
65–74 | 43 (35.2%) | 45 (39.1%) | |
75–99 | 44 (36.1%) | 46 (40.0%) | |
NYHA class | 0.071 | ||
Class I | 5 (4.1%) | 6 (5.2%) | |
Class II | 70 (57.4%) | 46 (40.0%) | |
Class III | 25 (20.5%) | 29 (25.2%) | |
Class IV | 1 (0.8%) | 5 (4.3%) | |
Missing | 21 (17.2%) | 29 (25.2%) | |
LBBB | 61 (50.0%) | 59 (51.3%) | 0.90 |
QRS duration (ms) | 161.5±29.1 | 159.7±29.2 | 0.62 |
LVEF (%) | 29.4±8.4 | 30.2±8.8 | 0.50 |
Ischaemic cardiomyopathy | 52 (42.6%) | 59 (51.3%) | 0.19 |
Hypertension | 48 (39.3%) | 41 (35.7%) | 0.59 |
Myocardial infarction | 41 (33.6%) | 55 (47.8%) | 0.034 |
Atrial fibrillation | 49 (40.2%) | 57 (49.6%) | 0.15 |
Chronic lung disease | 18 (14.8%) | 14 (12.2%) | 0.58 |
Diabetes | 21 (17.2%) | 32 (27.8%) | 0.061 |
Glomerular filtration rate (MDRD formula) | 62.2±27.5 | 59.4±21.1 | 0.38 |
Beta blocker | 103 (84.4%) | 98 (85.2%) | 1.00 |
ACEi / ARB | 106 (86.9%) | 99 (86.1%) | 1.00 |
MRA | 56 (45.9%) | 68 (59.1%) | 0.051 |
Upgrade | 15 (12.3%) | 27 (23.5%) | 0.027 |
ICD | 90 (73.8%) | 79 (68.7%) | 0.39 |
*P-value comparesusual care and the CRT- CPW. Tests used are Student t-test,Cochran-Mantel-Haenszel test, Fisher exact test. P-value<0.05 is considered significant
ACEi, angiotensin-converting enzyme-inhibitor; ARB, angiotensin II-receptor blocker; CRT, cardiac resynchronisation therapy; CRT-CPW, CRT care pathway; ICD, implantable cardioverter-defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.